{"id":"adapalene-benzoyl-peroxide-facial-gel","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Erythema"},{"rate":"10-20","effect":"Scaling or peeling"},{"rate":"10-15","effect":"Dryness"},{"rate":"5-15","effect":"Irritation"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL1200370","moleculeType":"Small molecule","molecularWeight":"242.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adapalene binds to retinoic acid receptors to regulate gene expression, promoting cell differentiation and reducing comedone formation. Benzoyl peroxide acts as an oxidizing agent that generates reactive oxygen species, killing Cutibacterium acnes (formerly Propionibacterium acnes) and reducing bacterial colonization. Together, they address multiple pathogenic factors in acne: follicular hyperkeratinization, bacterial proliferation, and inflammation.","oneSentence":"Adapalene is a retinoid that normalizes skin cell turnover and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:36.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT07473895","phase":"PHASE2","title":"Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT07421804","phase":"NA","title":"Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT06673641","phase":"PHASE1","title":"A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-05-13","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT00446043","phase":"PHASE3","title":"Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2004-02-17","conditions":"Acne Vulgaris","enrollment":452},{"nctId":"NCT03076320","phase":"PHASE1, PHASE2","title":"Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2017-03-27","conditions":"Acne Vulgaris Superficial Mixed Comedonal and Inflammatory","enrollment":82},{"nctId":"NCT01522456","phase":"PHASE4","title":"Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-04","conditions":"Acne Vulgaris","enrollment":73},{"nctId":"NCT03573115","phase":"NA","title":"Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery","status":"COMPLETED","sponsor":"Merete Haedersdal","startDate":"2018-01-04","conditions":"Acne Vulgaris, Microparticles","enrollment":16},{"nctId":"NCT03393494","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2017-12-13","conditions":"Acne Vulgaris","enrollment":825},{"nctId":"NCT03563365","phase":"PHASE4","title":"The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol","status":"TERMINATED","sponsor":"Yardley Dermatology Associates","startDate":"2018-06-04","conditions":"Acne Vulgaris","enrollment":43},{"nctId":"NCT00687908","phase":"PHASE3","title":"Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-11","conditions":"Acne","enrollment":243},{"nctId":"NCT01188538","phase":"PHASE4","title":"Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-03","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT01106807","phase":"PHASE2","title":"Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-04","conditions":"Acne","enrollment":73},{"nctId":"NCT00688064","phase":"PHASE3","title":"Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-08","conditions":"Severe Acne Vulgaris","enrollment":459},{"nctId":"NCT01014689","phase":"PHASE3","title":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":378},{"nctId":"NCT01474590","phase":"PHASE3","title":"Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-11","conditions":"Acne","enrollment":266},{"nctId":"NCT02932267","phase":"PHASE3","title":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-02-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT03457636","phase":"PHASE4","title":"The Use of Oracea and Epiduo Forte in Severe Acne Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2018-03-19","conditions":"Acne","enrollment":22},{"nctId":"NCT02731105","phase":"PHASE4","title":"Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-02","conditions":"Acne Vulgaris","enrollment":22},{"nctId":"NCT00658112","phase":"PHASE4","title":"Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2006-07","conditions":"Acne Vulgaris","enrollment":20},{"nctId":"NCT02557399","phase":"PHASE4","title":"DUAC® Early Onset Efficacy Study in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-07","conditions":"Acne Vulgaris","enrollment":350},{"nctId":"NCT00757523","phase":"PHASE4","title":"Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-09-10","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT00887484","phase":"PHASE4","title":"A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT00964223","phase":"PHASE4","title":"A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":28},{"nctId":"NCT00926367","phase":"PHASE4","title":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT01387048","phase":"PHASE4","title":"Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin","status":"COMPLETED","sponsor":"University of Magdeburg","startDate":"2011-08","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT00807014","phase":"PHASE4","title":"Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2006-11","conditions":"Acne Vulgaris","enrollment":169},{"nctId":"NCT01149330","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma Brasil Ltda.","startDate":"2010-07","conditions":"Acne Vulgaris","enrollment":75},{"nctId":"NCT00919191","phase":"PHASE4","title":"Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-04","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT00952523","phase":"PHASE4","title":"Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":162},{"nctId":"NCT00714714","phase":"PHASE4","title":"Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-01","conditions":"Acne Vulgaris","enrollment":25},{"nctId":"NCT01501799","phase":"NA","title":"A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2011-07","conditions":"Acne Vulgaris","enrollment":885}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epiduo Gel"],"phase":"marketed","status":"active","brandName":"Adapalene/Benzoyl Peroxide Facial Gel","genericName":"Adapalene/Benzoyl Peroxide Facial Gel","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adapalene is a retinoid that normalizes skin cell turnover and reduces inflammation, while benzoyl peroxide kills acne-causing bacteria and provides additional antimicrobial activity. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}